TORRENT PHARMACEUTICALS LTD. - 500420 - Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 21st October, 2022 at 06:30 P.M. to discuss the financial performance of the Company for the quarter and half year ended 30th September, 2022. TORRENT PHARMACEUTICALS LTD. - 500420 - Update On Acquisition Of Curatio Health Care (I) Private Limited
With reference to our earlier intimation dated 27-Sep-22 in relation to acquisition of 100% stake in Curatio Health Care (I) Private Limited, we hereby wish to inform that the transaction has been consummated today. Kindly take note of the above. TORRENT PHARMACEUTICALS LTD. - 500420 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Chintan M TrivediDesignation :- Company Secretary and Compliance Officer TORRENT PHARMACEUTICALS LTD. - 500420 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In compliance with the requirements under 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Compliance Certificate for the half year ended on 30th September, 2022. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Friday, 21-Oct-22, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-22.
Buy Torrent Pharmaceuticals; target of Rs 1724: Anand Rathi
Anand Rathi is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1724 in its research report dated September 28, 2022.
What Rs 2,000 crore Curatio Healthcare deal means for Torrent Pharma
Pharmaceutical analysts hold that the deal will play a significant role in the expansion of Torrent Pharma in various markets and positively impact its revenues in the near term. Curatio is a leading player in the cosmetic dermatology segment, having operations in India, Nepal, Sri Lanka, and the Philippines. TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The USFDA inspected our manufacturing facility at Indrad, Gujarat from 19-Sep-22 to 28-Sep-22. At the end of the inspection, we have been issued a 'Form 483' with 3 observations. None of these observations were related to data integrity. We will respond to the USFDA within stipulated timeline and work closely with USFDA to address the observations at the earliest. We will keep the stock exchanges informed of any material development relating to the above in the future. Please take the information on record.